Definium Therapeutics (DFTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.44
- Estimate
- -$0.55
- Surprise
- -162.3%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Definium Therapeutics (DFTX) reported a wider loss than forecast — diluted EPS of -$1.44 against the -$0.55 estimate (a 162.3% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates DFTX Sell at 5.5/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -162.3% surprise compares with a -65.8% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: DT120 ODT
- Concentration risk — Supplier: Catalent
- Quality below floor (1.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.00
- Price target
- $60.72
- Stop
- $36.17
- Upside to target
- +55.7%
- Reward-to-risk
- 5.8:1
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
DFTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.23B
- P/E (fwd)
- -20.7
- 52-week range
- $8.77–$49.70
- Off 52-week high
- 21.5%
- RSI (14)
- 26
- Volume vs avg
- 1.07×
- Score today
- 5.5/10